Status: Recruiting
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
Participants needed: 50
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Caribou Biosciences, Inc.Updated: Sep 25, 2025Locations: 16
Eligibility criteria
Documented diagnosis of relapsed/refractory multiple myeloma (MM) with measurabl... [+3]
Prior treatment with CAR-T cell therapy directed at any target. [+9]